← Back to Search

Other

MEM 3454 for Cognitive Impairment in Schizophrenia

Phase 2

Waitlist Available

Research Sponsored by Memory Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinically stable, as judged by the investigator, and in a non-acute phase for at least 12 weeks.

Diagnosis of schizophrenia (any subtype), assessed using a structured interview.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up weeks 2, 4, 6, 8, 10

Awards & highlights

Study Summary

This trial will test whether MEM 3454 is a safe and effective treatment for cognitive impairment associated with schizophrenia.

Who is the study for?

This trial is for adults with schizophrenia who have been stable on their current antipsychotic medication for at least one month and are not in an acute phase of illness. They must be fluent in English, able to consent, and can be smokers or non-smokers. People with other psychiatric conditions, recent hospitalization, early-stage schizophrenia, suicide risk, or substance abuse (except nicotine/caffeine) cannot join.Check my eligibility

What is being tested?

The study tests if MEM 3454 is safe and effective when added to existing antipsychotic treatment for those with cognitive issues due to schizophrenia. Participants will either receive MEM 3454 or a placebo without knowing which one they're getting.See study design

What are the potential side effects?

Potential side effects of MEM 3454 may include typical reactions seen with antipsychotics such as drowsiness, weight gain, dry mouth, restlessness or gastrointestinal issues; however specific side effects related to this drug will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition has been stable for at least 12 weeks.

Select...

I have been diagnosed with schizophrenia.

Select...

I have been diagnosed with schizophrenia.

Select...

My health has been stable for the last 3 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ weeks 2, 4, 6, 8, 10

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~weeks 2, 4, 6, 8, 10

This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 2, 4, 6, 8, 10 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline in the total composite score of the MATRICS cognitive battery at week 8.

Secondary outcome measures

Adverse events

Change from baseline in the total composite score of the MATRICS cognitive battery at Weeks 4 and 10

Change from baseline on the various cognition tests at Weeks 4, 8 and 10

+1 more

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: CExperimental Treatment1 Intervention

Group II: BExperimental Treatment1 Intervention

Group III: AExperimental Treatment1 Intervention

Group IV: DPlacebo Group1 Intervention

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memory PharmaceuticalsLead Sponsor

4 Previous Clinical Trials

335 Total Patients Enrolled

Media Library

MEM 3454 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00604760 — Phase 2

Cognitive Impairment Research Study Groups: A, C, D, B

Cognitive Impairment Clinical Trial 2023: MEM 3454 Highlights & Side Effects. Trial Name: NCT00604760 — Phase 2

MEM 3454 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00604760 — Phase 2

Cognitive Impairment Patient Testimony for trial: Trial Name: NCT00604760 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many centers are coordinating this experiment?

"There are 44 locations that offer this trial, including Coastal Communities Hospital in Santa Ana, Fort Lauderdale Hospital in Fort Lauderdale and TuKoi Clinical Research in Miami."

Answered by AI

Is the age range for this trial primarily above or below 65?

"The current trial is recruiting for patients between 18 and 55 years of age. However, there are 69 studies specifically targeting younger individuals and 695 trials that focus on seniors over 65."

Answered by AI

What is the current capacity for enrolment in this trial?

"Sadly, this clinical trial is not currently enrolling patients. It was originally posted in December 2007 and the last update occurred 5 days later that same month. Alternatively, 891 trials concerning schizophrenia are presently recruiting participants while a single study related to MEM 3454 has open recruitment slots available."

Answered by AI

What potential hazards does MEM 3454 pose to humans?

"Given that the trial is in Phase 2, without any efficacy data yet available, MEM 3454 was rated 2 on our safety scale."

Answered by AI

Is it still feasible for people to join the study?

"At present, this clinical trial is not enrolling any further patients. The study was first announced on December 1st 2007 and modified lastly on the 5th of December 2008. If you are looking for alternative trials, 891 clinical studies concerning schizophrenia presently require participants, with one such research project specifically searching for MEM 3454 users."

Answered by AI

To what extent has MEM 3454 been explored in other scientific inquiries?

"At this moment in time, one research study is being conducted concerning MEM 3454. Since it has yet to reach Phase 3, there are no active trials for the drug. Nonetheless, 44 different medical centres from Oklahoma City have begun conducting tests on this medication's efficacy and safety."

Answered by AI

Is this a fresh clinical trial?

"Presently, a single trial for MEM 3454 is taking place in 32 cities and 1 nation. Memory Pharmaceuticals initiated the first study of this drug back in 2007 with 160 patients; after achieving Phase 2 approval status, no additional trials have been instigated since then."

Answered by AI

What criteria must an individual meet in order to participate in this research?

"This clinical trial is seeking 160 individuals with schizophrenia aged between 18 and 55."

Answered by AI

Who else is applying?

What state do they live in?

Kentucky

California

Texas

How old are they?

18 - 65

What site did they apply to?

Pasadena Research Institute

Neuropsychiatric Research Center of Orange County

Collaborative NeuroScience Network, Inc.

Other

What portion of applicants met pre-screening criteria?

Did not meet criteria

Met criteria

How many prior treatments have patients received?

Why did patients apply to this trial?

I have schizophrenia and nothing is helping! So I am willing to try anything!

PatientReceived no prior treatments

I have been diagnosed with Schizophrenia and I'm interested in trying an experimental medication to reduce my symptoms. Thank you.

PatientReceived 2+ prior treatments

Because I do have medical problems that deal with how I I think and act. I have diabetes type 1 that is not control led I got it at 13 I'm 32 now it goes below 10 at times and as high as 1,800 at times I have proof from my hospital and my doctor said I need to be on medication for my mind. I'm also a drug abuser. I will always be but I'm clean of 2 years in August.

PatientReceived 2+ prior treatments